Curevac company information, Employees & Contact Information

BioNTech Initiates Public Exchange Offer to Acquire CureVac Shares for mRNA Cancer Immunotherapy Advancement Quiver Quantitative

CureVac 14D-9 filed as BioNTech exchange offer commences Stock Titan

CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates Yahoo Finance

BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer GlobeNewswire

BioNTech (Nasdaq: BNTX) offers ~$5.46 in ADSs per CureVac share; offer expires December 3 Stock Titan

CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE Yahoo Finance

[Form 6-K only / English only] CureVac CEO Alexander Zehnder Acquires Common Shares of Company Stock CureVac

GSK and CureVac to restructure collaboration into new licensing agreement GSK

An mRNA-encoded dominant-negative inhibitor of transcription factor RUNX1 suppresses vitreoretinal disease in experimental models Science | AAAS

CEPI awards US $34million contract to CureVac to advance The RNA Printer™–a mRNA vaccine platform that can rapidly combat multiple diseases CEPI

CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform CureVac

EQS-News: CureVac Announces Voting Results of General Meeting - boerse.de boerse.de

GSK and CureVac announce strategic mRNA technology collaboration GSK

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business Update CureVac

GSK and CureVac to develop next generation mRNA COVID-19 vaccines GSK

CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK CureVac

An mRNA-based FimH nanoparticle vaccine against uropathogenic Escherichia coli is highly immunogenic in rodents Frontiers

The clinical progress of mRNA vaccines and immunotherapies Nature

CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates ACCESS Newswire

Rapid and Accurate Quantification of RNA in Lipid Nanoparticles by Scatter-Free UV/Visible Spectroscopy ACS Publications

Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study GSK

GSK Gains $370 Million Upfront, Reduced Royalties in CureVac mRNA Patent Settlement Agreement with Pfizer, BioNTech Pharmaceutical Executive

What went wrong with CureVac's highly anticipated new mRNA vaccine for COVID-19? Science | AAAS

$740M Patent Settlement: CureVac Resolves Pfizer Dispute and Agrees to BioNTech Acquisition Deal Stock Titan

CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update Stock Titan

CureVac's CVGBM Trial: Promising Results Progress Pipeline (NASDAQ:CVAC) Seeking Alpha

Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines PR Newswire

The patent dispute over the breakthrough mRNA technology Frontiers

mRNA mediates passive vaccination against infectious agents, toxins, and tumors EMBO Press

Tesla chief Elon Musk teams up with Covid-19 player CureVac to build ‘RNA microfactories’ Endpoints News

The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines Frontiers

U.S. Offered ‘Large Sum’ to German Company for Access to Coronavirus Vaccine Research, German Officials Say The New York Times

An mRNA-encoded dominant-negative inhibitor of transcription factor RUNX1 suppresses vitreoretinal disease in experimental models Science | AAAS

mRNA mediates passive vaccination against infectious agents, toxins, and tumors EMBO Press

How to contact the Daily Bulletin FinancialContent

CVAC Stock Price and Chart — NASDAQ:CVAC TradingView

CureVac CEO Interview, Coronavirus Vaccine Development, Controversy businessinsider.com

CureVac NV (CVAC) Stock Price, Trades & News GuruFocus

Phase 1 Assessment of the Safety and Immunogenicity of an mRNA- Lipid Nanoparticle Vaccine Candidate Against SARS-CoV-2 in Human Volunteers medRxiv

CureVac's COVID-19 mRNA vaccine protects mice against aggressive coronavirus variant Fierce Biotech

Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025) ts2.tech